SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998; 338: 10891096.
  • 2
    Feig SA, D'Orsi CJ, Hendrick RE, et al. American College of Radiology guidelines for breast cancer. Am J Roentgenol. 1998; 171: 2933.
  • 3
    Chan HP, Wei J, Sahiner B, et al. Computer-aided detection system for breast masses on digital tomosynthesis mammograms: preliminary experience. Radiology. 2005; 237: 10751080.
  • 4
    Reiser I, Nichikawa RM, Giger ML, et al. Computerized detection of mass lesions in digital breast tomosynthesis images using two- and three dimensional radial gradient index segmentation. Technol Cancer Res Treat. 2004; 3: 437441.
  • 5
    Rafferty EA, Kopans DB, Wu T, Moore RH. Tomosynthesis: a new tool for breast cancer detection. Proceedings from the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8–11, 2005. Abstract from Plenary Session 5.
  • 6
    Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990; 82: 46.
  • 7
    Toi M, Band H, Kuroi K. The predictive value of angiogenesis for adjuvant therapy in breast cancer. Breast Cancer. 2000; 7: 311314.
  • 8
    Lee SK, Lee T, Lee KR, Su YG, Liu TJ. Evaluation of breast tumors with color Doppler imaging: a comparison with image-directed Doppler ultrasound. J Clin Ultrasound. 1995; 23: 367373.
  • 9
    Chao TC, Lo YF, Chen SC, Chen MF. Color Doppler ultrasound in benign and malignant breast tumors. Breast Cancer Res Treat. 1999; 57: 193199.
  • 10
    Waterman D, Madjar H, Sauerbrei W, Hirt V, Prompeler H, Stickeler E. Assessment of breast cancer vascularisation by Doppler ultrasound as a prognostic factor of survival. Oncol Rep. 2004; 11: 905910.
  • 11
    Boonjunwetwat D, Prueksadee J, Sampatanukul P, Chatamra K. Does color Doppler ultrasound vascularity predict the response to neoadjuvant chemotherapy in breast cancer? J Med Assoc Thai. 2005; 88: 13671372.
  • 12
    Kriege M, Brekelmans CTM, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004; 351: 427437.
  • 13
    Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography and clinical breast examination. JAMA. 2004; 292: 13171325.
  • 14
    MARIBS Study Group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicenter cohort study. Lancet. 2005; 365: 17691778.
  • 15
    Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MRI imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene. Preliminary results. Radiology. 2000; 215: 267279.
  • 16
    Lehman CD, Blume JD, Weatherall P, et al. Screening women at high risk for breast cancer with mammography and MRI. Cancer. 2005; 102: 18981905.
  • 17
    Podo F, Sardanelli F, Canese R, et al. The Italian multi-centre study on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res. 2002; 21( suppl): 115124.
  • 18
    Burak WEJr, Povoski SP, Yanssens TL, et al. Radiofrequency ablation of invasive breast cancer followed by delayed surgical excision. Proceedings of the 25th San Antonio Breast Cancer Symposium, San Antonio, Texas, December 10–14, 2003. Abstract 451.
  • 19
    Tse NY, Hoh Ck, Hawkins RA Zinner MJ, Dahlbom M, Choi Y. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg. 1992; 216234.
  • 20
    Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology. 1993; 187: 743750.
  • 21
    Gorres GW, Steinert HC, von Schulthess GK. PET and functional anatomic fusion imaging in lung and breast cancers. Cancer J. 2004; 10: 251261.
  • 22
    Weisenberger D. Positron emission mammography. Available at URL: http://www.jlab.org/div_dept/detector/pem Accessed November 27, 2006.
  • 23
    Levine EA, Freimani RI, Perrier NC, et al. Positron emission mammography: initial clinical results. Ann Surg Oncol. 2003; 10: 8691.
  • 24
    Rosen EL, Turkington TG, Soo MS, Baker JA, Coleman RE. Detection of primary breast carcinoma with a dedicated large-field-of-view FDG PET mammography device: initial experience. Radiology. 2005; 234: 527534.
  • 25
    Loo C, Lin A, Hirsch L, et al. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol Cancer Res Treat. 2004; 3: 3340.
  • 26
    West J. Gold nanoshells as a new treatment strategy for breast. Proceeding of the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8–11, 2005. Abstract MSI-2.
  • 27
    Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol. 1997; 24( suppl 10): S10-3S10-10.
  • 28
    Hudis C, Citron M, Berry D, et al. Five-year follow-up of INTC9741: dose-dense chemotherapy is safe and effective. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8–11, 2005. Abstract 41.
  • 29
    Sparano JA, Wang M, Martino S, et al. Phase 3 study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk-node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8–11, 2005. Abstract 48.
  • 30
    Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005; 97: 17121714.
  • 31
    Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21: 14311439.
  • 32
    Breast Cancer Update. Interview with Daniel F. Hayes, MD. Available from URL: http://www.breastcancerupdate.com/bcu2006/5/hayes.asp Accessed November 25, 2006.
  • 33
    Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000; 60: 18781886.
  • 34
    Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991; 325: 164170.
  • 35
    Siemann DW, Bibby MC, Dark GG. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res. 2005; 11: 416420.
  • 36
    Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 2006; 17: 961967.
  • 37
    Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol. 2006; 24: 36233628.
  • 38
    Burstein HJ, Spigel D, Kindsvogel K, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8–11, 2005. Abstract 4.
  • 39
    Bocci G, Tuccori M, Emmenegger U, et al. cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol. 2005; 16: 12431252.
  • 40
    Kolata G. In the war on cancer, a new kind of weapon. New York Times. May 7, 1991. Available at URL: http://query.nytimes.com/gst/fullpage.html?sec=health&res=9D0CE1D71131F934A35756C0A967958260 Accessed November 28, 2006.
  • 41
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118: 30303044.
  • 42
    Campoli M, Ferrone S, Zea Ah, et al. Mechanisms of tumor evasion. Cancer Treat Res. 2005; 123: 6188.
  • 43
    Radford KJ, Vari F, Hart DN. Vaccine strategies to treat lymphoproliferative disorders. Pathology. 2005; 37: 534550.
  • 44
    Molldrem JJ. Vaccination for leukemia. Biol Blood Marrow Transplant. 2006; 1218.
  • 45
    Kortylewski M, Kujawski M, Want T, et al. Inhibiting Stat 3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005; 11: 13141321.
  • 46
    Gillanders WE, Thalachallour M. Progress in the development of a breast cancer vaccine: mammaglobin A as an attractive target for vaccine therapy. Breast Dis Year Book Q. 2006; 17: 2628.
  • 47
    Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004; 10: 46994708.
  • 48
    Narayanan K, Jaramillo A, Benshoff ND, et al. Response of established human breast tumors to vaccination with mammaglobin-A cDNA. J Natl Cancer Inst. 2004; 96: 13881396.
  • 49
    Chopra A, Kim TS, O'Sullivan I, et al. Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine. Int J Cancer. 2006; 118: 28882898.
  • 50
    Singh R, Dominiecki ME, Jaffe EM, et al. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FBV/N mouse. J Immunol. 2005; 175: 36633673.
  • 51
    Kan C-Y, Iacopetta BJ, Lawson JS, et al. Identification of human papillomavirus DNA gene sequences in human breast cancer. Br J Cancer. 2005; 93: 946948.
  • 52
    Band V, Zajchowski D, Kulsea V, et al. Human papilloma virus DNAs immortalize human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci USA. 1990; 8: 463467.
  • 53
    Glaser SL, Hsu JL, Gulley ML. Epstein-Barr virus and breast cancer: state of the evidence for viral carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2004; 13: 688697.
  • 54
    Speck P, Longnecker R. Infection of breast epithelial cells with Epstein-Barr virus via cell-to-cell contact. J Natl Cancer Inst. 2000; 92: 18491851.
  • 55
    Bittner J. Some possible effect of nursing on the mammary tumor incidence. Science. 1936; 84: 162169.
  • 56
    Moore DH, Long CA, Vaidya AB, et al. Mammary tumor viruses. Adv Cancer Res. 1979; 29: 347415.
  • 57
    Etkind P, Du J, Khan A, et al. Mouse mammary tumor virus-like ENV gene sequences in human breast tumors and in a lymphoma of a breast cancer patient. Clin Cancer Res. 2000; 6: 12731278.